{"company":{"id":1949959,"name":"Sarepta","domain":"sarepta.com","url":"https://alion.io/company/sarepta"},"section":"news","answer":"Sarepta: 16 headlines on record, 8 headlines in the last 90 days. Its story counts 1 milestone.","figures":[{"label":"Headlines","value":"16"},{"label":"In 90 days","value":"8"},{"label":"Milestones","value":"1"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":7},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":1}],"news":[{"date":"2026-10-02","kind":"News","title":"Sarepta could be 'potential turnaround story' with catalysts lined up into 2027","source":"BioSpace","url":"https://biospace.com/drug-development/sarepta-could-be-potential-turnaround-story-with-catalysts-lined-up-into-2027"},{"date":"2026-10-01","kind":"Press release","title":"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 30, 2026","source":"BioSpace","url":"https://biospace.com/press-releases/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-september-30-2026"},{"date":"2026-09-30","kind":"News","title":"Sarepta Therapeutics stock falls 1.28 percent as DMD data land","source":"Sarepta Therapeutics stock falls 1.28 percent as DMD data land","url":"https://ad-hoc-news.de/boerse/news/nebenwerte/sarepta-therapeutics-stock-falls-1-28-percent-as-dmd-data-land/70206003"},{"date":"2026-09-30","kind":"News","title":"Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS ...","source":"marketscreener.com","url":"https://marketscreener.com/news/sarepta-therapeutics-presents-new-data-at-2026-world-muscle-society-annual-congress-demonstrating-sa-ce785ad2d18bf621"},{"date":"2026-09-30","kind":"News","title":"Sarepta Therapeutics, Inc. Presents New Data Demonstrating Safety And Clinically Meaningful Functional Benefit Of ELEVIDYS In Older Ambulatory Patients With Duchenne","source":"marketscreener.com","url":"https://marketscreener.com/news/sarepta-therapeutics-inc-presents-new-data-demonstrating-safety-and-clinically-meaningful-function-ce785ad3d88df721"},{"date":"2026-09-26","kind":"News","title":"Why Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPenn","source":"YahooFinance","url":"https://finance.yahoo.com/healthcare/articles/why-sarepta-therapeutics-srpt-down-200705416.html"},{"date":"2026-09-23","kind":"News","title":"Regenxbio settles patent dispute with Sarepta for $39M","source":"streetinsider.com","url":"https://streetinsider.com/Corporate+News/Regenxbio+settles+patent+dispute+with+Sarepta+for+%2439M/27096817.html"}],"story":[{"title":"Board appointment John Martin, Director · SEC Form D","url":"https://www.sec.gov/Archives/edgar/data/873303/000090445420000249/"}],"as_of":"2026-11-18","cite":"Sarepta, News. Alion, Nov 18, 2026. https://alion.io/company/sarepta/news","html_url":"https://alion.io/company/sarepta/news","json_url":"https://alion.io/company/sarepta/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-18T20:08:08Z"}}